Leading Ophthalmologists to Discuss the Value of IRIDEX Solutions at AAO > IRIDEX



Glaucoma and Retina Specialists Will Discuss the Benefits of MicroPulse® Technology

MOUNTAIN VIEW, Calif., Oct. 23, 2018 (GLOBE NEWSWIRE) -- IRIDEX Corporation (Nasdaq:IRIX), a leading provider of innovative laser systems in ophthalmology, will be hosting a series of panel discussions at the American Academy of Ophthalmology (AAO) in Chicago, IL on October 27-29, 2018. Twenty-seven leading glaucoma and retina specialists from around the world will highlight how they are using IRIDEX lasers in MicroPulse® mode to treat early to late stage glaucoma and several retina diseases.

“Laser treatment for glaucoma has evolved significantly, allowing ophthalmologists to treat a wider variety of patients. Treatment of glaucoma with IRIDEX’s MicroPulse P3 device extends well beyond refractory stage applications. In patients with moderate to severe disease, I have had great success with open angle and angle closure glaucoma. Moreover, the versatility of the procedure with the MicroPulse P3 gives us the opportunity to extend this treatment to patients with good central vision and those with earlier stage glaucoma. At the upcoming AAO meeting, I plan to share clinical data during a poster session and during IRIDEX’s Forum Panel Presentations,” states Sandra Fernando-Sieminski, MD, Director of Glaucoma Service at University at Buffalo in New York.

Lawrence Morse, MD, PhD, Professor of Ophthalmology and Director of Retina Services at the University of California Davis, shared, “MicroPulse Laser Therapy is an effective and gentle procedure for the treatment of diabetic macular edema (DME) and other retinal diseases. My research and clinical experience confirm that the combination of MicroPulse and anti-VEGF therapy may help to reduce the treatment burden on patients with DME. I am looking forward to discussing the many benefits of MicroPulse with colleagues at one of IRIDEX’s Forum Panel Presentations.”

The roundtable discussions will take place on Saturday, October 27 through Monday, October 29th. The program is as follows:

Saturday, October 27

10:30-11:30 AM: Glaucoma Panel - MicroPulse: Myth or Messiah?

  • Oluwatosin Smith, MD; Michael Giovingo, MD; Rohit Krishna, MD; David Gossage, DO

1:30-2:30 PM: Retina Panel - MicroPulse laser therapy for CSCR and DME retinal disorders

  • Larry Morse, MD, PhD; Glenn Yiu, MD, PhD; Caesar Luo, MD, FACS; Roger Goldberg, MD, MBA

3:00-4:00 PM: Glaucoma Presentation - MicroPulse Cyclophotocoagulation: A look at long term efficacy and outcomes

  • Nathan Radcliffe, MD

Sunday, October 28

9:00-9:30 AM: Retina Presentation - The mechanism of HSP expression post MicroPulse therapy for retinal disorders

  • Kishiko Ohkoshi, MD, PhD (Japan)

10:30-11:30 AM: Glaucoma Panel - MicroPulse TSCPC: It is not just for end stage glaucoma

  • Robert Noecker, MD, MBA; Sandra Fernando Sieminski, MD; Syril K. Dorairaj, MD, FACS; Bret Crumpton, DO

1:30-2:30 PM: Retina Panel - When injections are not enough: learn about your therapeutic choices with MicroPulse therapy

  • Marco Zarbin, MD, PhD; Ted Leng, MD, FACS; Julia Schulman, MD; Dana Dupree, MD; Jeevan Mathura, MD

3:00-4:00 PM: Comprehensive Presentation - 2- and 3-year outcomes for mild glaucoma with the Cyclo G6® laser

  • Ahad Mahootchi, MD

Monday, October 29

10:30-11:30 AM: Glaucoma Panel - Experiences with MicroPulse P3™ procedure in the US and abroad: A non-incisional approach to glaucoma treatment

  • Jeffrey Kammer, MD; Arthur Resende, MD; Vital Paulino Costa, MD; Shamil Patel, MD

1:30-2:30 PM: Retina Panel: MicroPulse and CSCR: A game changer

  • Munir Escaf, MD (Colombia); Sergio Rojas, MD (Mexico); Karen Barraza, MD (Peru)

In addition to the panels, IRIDEX’s glaucoma treatment will be featured at AAO’s Skills Transfer Lab on Sunday, and IRIDEX will be offering hands-on demos in the booth, #3721. To learn more about joining these events please visit iridex.com/aao.

Data of Note

IRIDEX technologies will also be represented through scientific data presentations. Two data sets will review positive results from a total of 68 eyes treating with MicroPulse.

  • PO096 - Success Rate and Safety of MicroPulse Trans-scleral CPC With Variable Treatment Durations in Glaucoma
    Sunday, October 28th; 12:45 PM
    Author: Dr Robert Noecker
  • PO384 - Safety and Efficacy of MicroPulse Trans-scleral CPC in Eyes with Good Central Vision
    Monday, October 29th; 12:45 PM
    Author: Sandra Sieminski, MD

The AAO meeting anticipates welcoming over 20,000+ ophthalmologists, health professionals and industry personnel from around the world will convene in Chicago to hear from thought leaders, gain insights into practice management trends and get hands-on experience with cutting-edge treatment techniques.


IRIDEX is a worldwide leader in developing innovative and versatile laser-based medical systems, delivery devices and consumable instrumentation for the ophthalmology market. The Company’s proprietary MicroPulse® technology delivers a differentiated treatment that provides safe, effective, and proven treatment for targeted sight-threatening eye conditions. IRIDEX’s current product line is used for the treatment of glaucoma, diabetic macular edema (DME) and other retinal diseases.  IRIDEX products are sold in the United States and Germany through a direct sales force and in more than 100 countries through a network of independent distributors. For more information, visit www.iridex.com.

Media Contact:

Jamie Hall
Pascale Communications, LLC.

Investor Relations

Lynn Pieper Lewis or Leigh Salvo

Posted in: News
Actions: E-mail | Permalink |